logo-loader
viewArix Bioscience PLC

Arix appoints entrepreneur in residence to source European investment opportunities

Iacone previously served as director and global head of the Rare Diseases Research division at Swiss pharma giant Roche

Arix Bioscience PLC - Arix appoints entrepreneur in residence to source European investment opportunities

Arix Bioscience PLC (LON:ARIX) has appointed Roberto Iacone as its entrepreneur in residence (EIR) to assist in company creation and the sourcing of early stage investment opportunities in Europe.

Iacone previously served as director and global head of the rare diseases research division at Swiss pharma giant Roche, where he was responsible for generating disease area strategies and advancing several assets for immunological and neurological disease from discovery to early clinical development.

READ: Arix Biosciences portfolio company Aura encouraged by trial results of eye cancer treatment

Arix said the new role will see Iacone sourcing potential investment opportunities that the company can jointly fund with its partner Takeda Ventures, the strategic venture investing arm of Takeda Pharmaceuticals.

“Roberto brings a wealth of international experience and excellent track record of creating companies that foster exciting science. He will be a valuable addition to Arix and Takeda as we work together to create innovative new companies that address serious medical need”, said Arix chief executive Joe Anderson.

Arix shares were steady at 78.5p in lunchtime trading on Monday.

Quick facts: Arix Bioscience PLC

Price: 95.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £129.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience associate talks through current promising coronavirus...

Arix Bioscience PLC (LON:ARIX) Investment Associate Tim Xu tells Proactive what he believes are promising therapeutics currently being innovated by a variety of biotechs around the word. Xu, who recently published a blog post entitled "How close are we to a COVID-19 cure? A biotech VC...

on 21/4/20

2 min read